PCR

ECCMID 2023: Shionogi to Present Data Showing COVID-19 Symptom Recurrence is Not Associated with Ensitrelvir Treatment

Retrieved on: 
Tuesday, April 4, 2023

: S-217622, hereafter “ensitrelvir”) will be published as posters at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark 15 - 18 April 2023.

Key Points: 
  • : S-217622, hereafter “ensitrelvir”) will be published as posters at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark 15 - 18 April 2023.
  • Ensitrelvir, known as Xocova® 125 mg tablet in Japan, received emergency regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for the treatment of SARS-CoV-2 infection.
  • The first late-breaking poster presentation included a post-hoc analysis of the Phase 3 part showing that viral rebound and symptom recurrence were infrequently seen up to 21 days after treatment with ensitrelvir.
  • Symptom recurrence was rare and was not associated with viral RNA rebound.

Epsilyte Unveils EPS Made with Post-Consumer Recycled Content

Retrieved on: 
Tuesday, April 4, 2023

Epsilyte, a leading North American producer of advanced materials, unveiled a product with a minimum of 50% certified post-consumer recycled (PCR) content.

Key Points: 
  • Epsilyte, a leading North American producer of advanced materials, unveiled a product with a minimum of 50% certified post-consumer recycled (PCR) content.
  • “Increasing the recycled content in our products while also maintaining quality performance is essential and is just the beginning for Epsilyte,” said Chad Zielinski, Research Supervisor responsible for this innovation.
  • “After our learnings and success with 124LR, we realize advanced products made with 100% recycled polystyrene are possible.
  • Cutting-edge development of advanced products that enhance sustainability for Epsilyte, its customers, and the world will remain a key component of Epsilyte’s growth strategy.

Promega to Award $15,000 Grants to Researchers Using qPCR

Retrieved on: 
Monday, April 3, 2023

Early-career researchers working with real-time quantitative PCR (qPCR) can advance their project through a grant offered by Promega Corporation.

Key Points: 
  • Early-career researchers working with real-time quantitative PCR (qPCR) can advance their project through a grant offered by Promega Corporation.
  • The 2023 qPCR Grant will award $15,000 in free Promega products to three academic life scientists incorporating the technique into their research.
  • “This grant will help the recipients leverage one of the most powerful techniques in molecular biology research,” says Promega Product Marketing Manager Gabriela Saldanha.
  • Past winners used Promega qPCR reagents to study circadian rhythms in Antarctic krill and viruses affecting bananas grown in the Philippines.

Cellecta, Inc. Launches DriverMap™ Adaptive Immune Receptor (AIR) Assay to Provide Greater Insights into Immune Repertoire Diversity by Profiling T-Cell and B-Cell Receptor Variability in Genomic DNA

Retrieved on: 
Wednesday, April 12, 2023

MOUNTAIN VIEW, Calif., April 12, 2023 /PRNewswire/ -- Cellecta, Inc. today announced the launch of the DriverMap™ Adaptive Immune Receptor DNA (AIR-DNA) TCR and BCR kits which provide rapid, single-tube PCR-based assays to analyze the genomic diversity of receptors from T-cells or B-cells from a wide range of sample types, including whole blood, tissue biopsies, FFPE and more.

Key Points: 
  • The multiplex-PCR assays profile the variations of the four T-cell receptor (TCR) or three B-cell receptor (BCR) chains present in the genomic DNA of immune samples.
  • The assay results are obtained through next generation sequencing and provide important information on the abundance and diversity of T- or B-cell clonotypes in each sample.
  • "We are pleased to introduce the DriverMap AIR-DNA assays, which along with our AIR-RNA profiling assays provide researchers with more effective tools for immune receptor repertoire profiling.
  • In addition to offering the DriverMap AIR-DNA and AIR-RNA kits, Cellecta continues to provide the DriverMap AIR-DNA or AIR-RNA Profiling assays as a service.

Global Biomarker Technologies Market to 2027: Escalating Demand for Early and Effective Diagnosis Drives Growth

Retrieved on: 
Tuesday, April 11, 2023

This, coupled with the escalating demand for early and effective diagnosis, represents one of the key factors positively influencing the market.

Key Points: 
  • This, coupled with the escalating demand for early and effective diagnosis, represents one of the key factors positively influencing the market.
  • Key Questions Answered in This Report:
    How has the global biomarker technologies market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global biomarker technologies market?
  • What is the structure of the global biomarker technologies market and who are the key players?

Molecular Designs releases their new Simplicity™ Gastrointestinal Pathogen Panel

Retrieved on: 
Tuesday, April 11, 2023

BIRMINGHAM, Ala., April 11, 2023 /PRNewswire/ -- Molecular Designs, a developer and manufacturer of molecular infectious disease assays , announces the release of its new Simplicity™ Gastrointestinal Pathogen Panel for the detection of causative agents of gastrointestinal (GI) tract infections.

Key Points: 
  • BIRMINGHAM, Ala., April 11, 2023 /PRNewswire/ -- Molecular Designs, a developer and manufacturer of molecular infectious disease assays , announces the release of its new Simplicity™ Gastrointestinal Pathogen Panel for the detection of causative agents of gastrointestinal (GI) tract infections.
  • The GI panel is a multiplex PCR assay that identifies nucleic acids from 16 different organisms, from a single sample.
  • Molecular Designs assays are manufactured to GMP and ISO 13485:2016 standards and are compatible with most PCR platforms.
  • "Our Simplicity Gastrointestinal Pathogen Panel is available to reference and hospital laboratories," said Robert Crisp , Ph.D., Vice President of Research & Development at Molecular Designs.

Synthego Launches Express Cell Pools for Faster, More Efficient Genome Editing

Retrieved on: 
Wednesday, April 5, 2023

REDWOOD CITY, Calif., April 5, 2023 /PRNewswire/ -- Synthego Corp., a leading provider of genome engineering solutions, has announced the launch of Express Knockout Cell Pools, a new product offering that revolutionizes access to CRISPR-mediated gene editing by providing researchers access to a more efficient and more reliable approach to obtain knockout cell pools at unparalleled speed and scale.

Key Points: 
  • REDWOOD CITY, Calif., April 5, 2023 /PRNewswire/ -- Synthego Corp., a leading provider of genome engineering solutions, has announced the launch of Express Knockout Cell Pools , a new product offering that revolutionizes access to CRISPR-mediated gene editing by providing researchers access to a more efficient and more reliable approach to obtain knockout cell pools at unparalleled speed and scale.
  • Bypassing the researcher's need to design, optimize, and execute a CRISPR workflow, Express Knockout Cell Pools will disrupt how researchers think about their CRISPR-editing needs.
  • Increased confidence in results: Express Knockout Cell Pools use Synthego's proprietary multi-guide technology to target protein-coding genes, increasing editing efficiency and maximizing the likelihood of functional knockout.
  • "With the launch of our new product line, Express Cell Pools, we offer an affordable, fast, efficient, and reliable way for researchers to obtain edited cell pools that can be used directly in many assays.

NOW® Launches NOW® Kids + NOW® Baby Clean Care

Retrieved on: 
Wednesday, April 5, 2023

CHICAGO, April 5, 2023 /PRNewswire/ -- NOW® has been empowering the healthy living community for 55 years and the family-owned brand is thrilled to launch NOW® Kids + NOW® Baby, which is available DTC and at select retailers nationwide. NOW® Kids + NOW® Baby offers quality supplements, toothpastes and body care products that are formulated with clean and functional ingredients – and without harsh or irritating chemicals – to care for the little loves in your life. With the launch of NOW® Kids + NOW® Baby, NOW® is your one-stop shop covering the health and wellness needs of the entire family. 

Key Points: 
  • NOW® Kids + NOW® Baby offers quality supplements, toothpastes and body care products that are formulated with clean and functional ingredients – and without harsh or irritating chemicals – to care for the little loves in your life.
  • With the launch of NOW® Kids + NOW® Baby, NOW® is your one-stop shop covering the health and wellness needs of the entire family.
  • According to Tina Tews, Personal Care Brand Manager, "Our body care products were created and tested by loving Moms at NOW, to ensure they would feel comfortable using them on their own kids.
  • Follow NOW @nowfoodsofficial on Instagram and Facebook and @NOWFoods on Twitter for more on NOW® Kids + NOW® Baby.

TATAA Biocenter expands its bioanalytical services with HTG certification

Retrieved on: 
Friday, March 31, 2023

This certification will enable TATAA to offer high-throughput, multiplex gene expression profiling to its customers, and expand its portfolio of molecular analysis services.

Key Points: 
  • This certification will enable TATAA to offer high-throughput, multiplex gene expression profiling to its customers, and expand its portfolio of molecular analysis services.
  • HTG Molecular Diagnostics is a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, HTG EdgeSeq™.
  • "We are excited to be a certified qualified service provider for HTG technology," said founder and CEO of TATAA Biocenter Mikael Kubista.
  • TATAA Biocenter is a pioneer in qPCR, digital PCR, and Next-Generation Sequencing (NGS) services and products, serving customers in academia, industry, and healthcare.

TATAA Biocenter expands its bioanalytical services with HTG certification

Retrieved on: 
Friday, March 31, 2023

This certification will enable TATAA to offer high-throughput, multiplex gene expression profiling to its customers, and expand its portfolio of molecular analysis services.

Key Points: 
  • This certification will enable TATAA to offer high-throughput, multiplex gene expression profiling to its customers, and expand its portfolio of molecular analysis services.
  • HTG Molecular Diagnostics is a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, HTG EdgeSeq™.
  • "We are excited to be a certified qualified service provider for HTG technology," said founder and CEO of TATAA Biocenter Mikael Kubista.
  • TATAA Biocenter is a pioneer in qPCR, digital PCR, and Next-Generation Sequencing (NGS) services and products, serving customers in academia, industry, and healthcare.